Donepezil for severe Alzheimer's disease

Lancet

Volumn 367, Issue 9516, 2006, Pages 1031-1032

  Hogan, David B ^a  

^a Health Sciences Centre Calgary   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONFIDENCE INTERVAL; DAILY LIFE ACTIVITY; DATA ANALYSIS; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MINI MENTAL STATE EXAMINATION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; HOSPITALIZATION; LONG TERM CARE; NOTE; PATIENT; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; LONG-TERM CARE; PATIENT DROPOUTS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 33645750171     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68395-5     Document Type: Note

References (10)

1. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367 (2006) 1057-1065
2. Streiner D. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 47 (2002) 68-75
3. Unnebrink K., and Windeler J. Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 20 (2001) 3931-3946
4. Panisset M., Roudlier M., Saxton J., and Boller F. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol 51 (1994) 41-45
5. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 suppl 2 (1997) S33-S39
6. Van Walraven C., Mahin J., Moher D., Bohm C., and Laupacis A. Surveying physicians to determine minimal important difference: implications for sample size calculation. J Clin Epidemiol 52 (1999) 717-723
7. Lopez O., Becker J., Wisniewski S., Saxton J., Kaufer D., and DeKosky S. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72 (2002) 310-314
8. Gasper M., Ott B., and Lapane K. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?. Am J Geriatr Pharmacother 3 (2005) 1-7
9. In: Last J. (Ed). A dictionary of epidemiology. 4th edn. (2001), Oxford University Press, Oxford 129
10. Rockwood K., Graham J., and Fay S. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 73 (2002) 500-507